The bcl-2 and caspase families are important regulators of programmed cell death in experimental models of ischemic, excitotoxic, and traumatic brain injury. The Bcl-2 family members Bcl-2 and Bcl-x L suppress programmed cell death, whereas Bax promotes programmed cell death. Activated caspase-1 (interleukin-1␤ converting enzyme) and caspase-3 (Yama/Apopain/Cpp32) cleave proteins that are important in maintaining cytoskeletal integrity and DNA repair, and activate deoxyribonucleases, producing cell death with morphological features of apoptosis. To address the question of whether these Bcl-2 and caspase family members participate in the process of delayed neuronal death in humans, we examined brain tissue samples removed from adult patients during surgical decompression for intracranial hypertension in the acute phase after traumatic brain injury (n‫)8؍‬ and compared these samples to brain tissue obtained at autopsy from non-trauma patients (n‫.)6؍‬ An increase in Bcl-2 but not Bcl-x L or Bax, cleavage of caspase-1, up-regulation and cleavage of caspase-3, and evidence for DNA fragmentation with both apoptotic and necrotic morphologies were found in tissue from traumatic brain injury patients compared with controls. These findings are the first to demonstrate that programmed cell death occurs in human brain after acute injury, and identify potential pharmacological and molecular targets for the treatment of human head injury.-Clark, R. S. B., Kochanek, P. M., Chen, M., Watkins, S. C., Marion, D. W., Chen, J., Hamilton, R. L., Loeffert, J. E., Graham, S. H. Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury. FASEB J. 13, 813-821 (1999)
structures, experimental models suggest that a significant amount of damage due to TBI occurs after the trauma as a result of secondary insults. Thus, pharmacological treatments administered after TBI that target secondary cellular injury and subsequent cell death need to be explored.
Programmed cell death (PCD) is the genetic mechanism by which cells are eliminated during development and is the physiological mechanism by which superfluous cells are removed in the adult animal. Cells that die via PCD often undergo distinct morphological changes known as apoptosis and cleave their DNA into small fragments. Recently, the genes that control PCD in the mammalian neuron have been identified. These genes include the caspase family of cysteine proteases [including interleukin-1␤ converting enzyme (ICE) and cpp32] that promote PCD and a family of genes that are homologous to the oncogene Bcl-2 that either promote or suppress cell death. It has been proposed that the interaction between Bcl-2 family members that promote (such as Bax) and suppress (such as Bcl-2 and Bcl-x L ) apoptosis determines whether cells undergo PCD (1, 2) .
PCD may occur in pathological as well as physiological cell death. Dysregulation of genes that control PCD may exacerbate cell death in disease and result in morphological changes with both necrotic and apoptotic characteristics (3, 4) . One precipitant for apoptosis in neurons is axonal injury (5, 6) , a common event after TBI (7) . Several reports in experimental models suggest that PCD occurs after TBI (8 -13) . Furthermore, dysregulation of expression of the Bcl-2 and caspase family genes has been observed in rat TBI models. Bcl-2 is induced in neurons in vulnerable regions of brain after TBI in rats and many neurons lacking Bcl-2 exhibit apoptotic morphologies (11) . Yakovlev et al. showed that caspase-1 and caspase-3 are activated and their expression increased after TBI in rats (9) . In preliminary reports, evidence for DNA fragmentation was seen in patients after fatal head injury (14, 15) . Evidence for PCD has also been reported in neurodegenerative diseases including Alzheimer and Parkinson disease (16, 18) .
Although the results of the experimental studies in rodent models of TBI are compelling, whether dysregulation of death regulatory genes occurs in human head injury is not known. Verifying that mechanisms operating in animal models are relevant to human disease is particularly important in studies of TBI, where encouraging results in rodent models have failed to translate into clinically useful therapies (19) . In this study, we show that expression of the Bcl-2 and caspase families of cell death-regulatory proteins are altered in humans after TBI, and provide evidence that PCD participates in neuronal cell death seen after TBI in humans.
MATERIALS AND METHODS

Human brain tissue samples
This study was approved by the Biomedical Institutional Review Board at the University of Pittsburgh, informed consent was obtained from the legal next of kin for each patient (approval no. 9502101), or approval was granted for existing tissue specimens (approval no. 970873). Brain tissue samples were obtained from patients who underwent a decompressive craniectomy as part of the management of life-threatening intracranial hypertension after TBI, i.e., clinical or radiographic evidence of cerebral herniation, impending cerebral herniation, or significant mass effect. The samples were collected after surgical resection of the injured area of brain and were residual tissue that would otherwise have been discarded. Samples were from injured temporal (nϭ6) or frontal (nϭ2) lobe cortex. Tissue was immediately frozen and stored at Ϫ70°C until used for analysis.
Patients in the study were admitted to the University of Pittsburgh Medical Center between August 1995 and November 1996. Clinical variables for patients after TBI are shown in Table 1 . The average age of the patients was 35.9 Ϯ 4.4 years. The median admission Glasgow Coma Scale score (20) was 5.5 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The median Glasgow Outcome Scale score (21) at 3 months after injury was 3 [1] [2] [3] [4] [5] . The study was undertaken during the prospective, randomized evaluation of the effect of moderate hypothermia (32°C for 24 h) vs. normothermia (37°C for 24 h) on neurological outcome after closed head injury (22) . Five of eight patients were enrolled in the hypothermia study: two were in the hypothermia (patients T1 and T8) and three were in the normothermia (patients T3, T5, and T7) treatment groups.
Control samples were from frozen post-mortem brain specimens obtained from patients who died of causes not related to central nervous system trauma. Samples were from temporal lobe cortex and were originally collected between April and October 1996. Clinical variables for control patients are shown in Table 2 . The average age of the patients was 52.2 Ϯ 9.0 years. The median post-mortem time was 8.8 Ϯ 2.9 h. 
Western blot analysis
A sample of contused cerebral cortex from each TBI patient and temporal lobe cortex from each control patient was analyzed by immunoblotting. Each sample was homogenized in lysis buffer containing 0.1 M NaCl, 0.01 M Tris, 0.1 mM EDTA, and the protease inhibitors chymostatin 2 g/ml, leupeptin 2 g/ml, pepstatin 2 g/ml, and phenylmethylsulfonyl fluoride 100 g/ml. Lysates were centrifuged at 14,000 rpm for 30 min at 4°C and boiled in loading buffer for 5 min. Fifty-microgram protein samples, as determined by A 280 , were loaded on sodium dodecyl sulfate-polyacrylamide gels, separated electrophoretically, and transferred to a Hybond-ECL nitrocellulose membrane (Amersham, Arlington Heights, IL) overnight. The transferred membranes were incubated in either the primary antibody against Bcl-2 (1:200 dilution), Bcl-x L (1:1000 dilution), Bax (1:1000 dilution), the p10 fragment of caspase-1 (1:500 dilution), or caspase-3 (monoclonal 1:1000 dilution; polyclonal 1:500 dilution) at room temperature for 1 h. After washing three times in phosphatebuffered saline (PBS) containing 0.1% Tween-20, the appropriate secondary antibody was applied at a 1:3000 dilution for 1 h. The membrane was washed in PBS containing 0.1% Tween-20 three times over 25 min, then incubated in commercial enhanced chemiluminescence reagents (New England Nuclear Life Science Products, Boston, MA) and exposed to Fuji RX film (Fuji, Tokyo, Japan). For each antibody, two gels were run simultaneously with three control and four TBI samples each, and the two corresponding membranes were exposed on the same X-ray film. This was done so that for each protein examined each sample was treated with identical electrophoresis and transfer times, antibody concentrations, incubation times, exposure to chemiluminescent reagents, and film exposure times. Autoradiogram signals were quantified by a gel densitometric scanning program (MCID, St. Catherines, Ontario, Canada). The relative protein levels were determined from the relative optical densities of the corresponding protein bands and were normalized to background values obtained on the same lane.
A preabsorption control experiment was performed using the caspase-1 p10 antibody and the commercially available peptide (Santa Cruz Biotechnologies). A 1:10 solution of antibody to peptide was incubated at 4°C overnight. Pairs of control and TBI samples (50 g) were run on a single gel and transferred to a nitrocellulose membrane as described above. The membrane was cut, one pair of samples was incubated in primary antibody, the other was incubated in primary antibody with peptide, and Western blot analysis was completed as described above.
Immunocytochemistry
Immunocytochemistry for Bcl-2, Bax, and caspase-3 was also performed on sections from contused brain from four TBI patients and temporal lobe cortex from four control patients.
Previously frozen specimens were post-fixed for 1 h in ice-cold 2% paraformaldehyde, then snap frozen in 2-methylbutane in liquid nitrogen. Specimens were cut in 10-M sections using a cryostat and mounted on glass slides. Slides were washed three times with PBS, and then washed three times in PBS containing 0.5% bovine serum albumin and 0.15% glycine (buffer A). Nonspecific activity was blocked with 5% normal goat serum in buffer A. Brain sections were then incubated overnight at room temperature in a 1:100 dilution of antibody against Bcl-2, a 1:300 dilution of antibody against Bax, or a 1:100 dilution of antibody against caspase-3. Sections were washed three times in buffer A and then incubated for 1 h in a 1:3000 dilution of goat anti-mouse Cy3.18 immunoconjugate (Jackson Immunochemicals, West Grove, PA). Sections were then washed three times in buffer A and three times in PBS (5 min/wash), mounted in gelvatol, and coverslipped for light microscopy. To label cell nuclei, bis-benzamide (Sigma, St. Louis, MO) diluted in sterile water was applied to some sections for 30 s before coverslipping. Sections were examined with an Olympus light microscope equipped for epifluorescent illumination. Images were collected using an integrating three-chip Sony color video camera (700 ϫ 600 pixels) equipped with a color frame grabber board. All images were collected while integrating at 4 frames/s using excitation/ emission wavelengths of 550/565 nm (red) and 346/460 nm (blue). To discriminate between immunolabeling and nonspecific autofluorescence, sections were also examined using an excitation/emission wavelength of 494/520 nm (green) with a dual-pass cube. In sections from each specimen, the primary antibody was omitted to assess for nonspecific binding of the secondary antibody.
Terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick-end labeling (TUNEL)
In situ labeling of DNA fragmentation using TUNEL was performed on separate brain sections from six TBI patients and six control patients with the use of a diaminobenzidine colorimetric method for light-microscopic analysis as described previously (10) . Briefly, frozen 20-M coronal sections were cut using a cryostat and mounted on glass slides. Sections were fixed in 10% neutral buffered formalin for 10 min at room temperature followed by ethanol:acetic acid (2:1) for 5 min at Ϫ20°C. Sections were then incubated in 3% Triton X-100 (Sigma) at room temperature for 1 h, then placed in 3% H 2 O 2 and 30% methanol in PBS for 20 min. Sections were then incubated in 300 U/ml terminal deoxynucleotidyl transferase and 20 nmol/ml biotin-16-dUTP (Boehringer Mannheim, Indianapolis, IN) in 1 ml 1ϫ buffer at 37°C for 90 min, washed with PBS three times, incubated in avidin-biotin complex (ABC standard kit, Vector Labs, Burlingame, CA), and TUNEL visualized with diaminobenzidine (Vector Labs). After observation of TUNEL-positive cells, coverslips were removed and sections were counterstained with hematoxylin and re-coverslipped.
Statistical analysis
All data are presented as mean Ϯ standard error of the mean or median (range) where appropriate. Comparisons of relative protein levels between TBI patients and control patients were made using a Mann-Whitney rank sum test. Statistics were performed using SigmaStat software (Jandel Scientific, San Rafael, CA).
RESULTS
Bcl-2, Bcl-x L , and Bax protein expression after TBI
To determine whether TBI leads to changes in Bcl-2 family protein levels in humans, we examined brain tissue samples from patients after severe TBI (Table  1) and compared them to post-mortem brain specimens obtained from patients who died of causes not related to central nervous system trauma ( Table 2) . In vivo experimental models have shown that Bcl-2, Bcl-x L , and Bax protein levels are altered after ischemic, excitotoxic, and TBI (11, (23) (24) (25) . Bcl-2 is minimally present, whereas both Bcl-x L and Bax are constitutively expressed in normal adult rat brain (11, 24 -26) . Western blots and relative protein levels demonstrated that Bcl-2 was minimally present in control patients, and was increased 17-fold in patients after TBI compared with controls (Fig. 1,  Pϭ0.020) . In contrast to Bcl-2, Bcl-x L and Bax were detected in most of the control samples and there was no difference in relative levels of Bcl-x L or Bax in patients after TBI compared with controls (Fig. 1,  Pϭ0.662 and 0.775, respectively) . The changes in expression of Bcl-2, Bcl-x L , and Bax after TBI in humans are consistent with experimental models of brain injury.
To determine cell types expressing Bcl-2 family proteins, and whether the relative Bcl-2 family protein levels were related to protein expression in parenchymal cells vs. hemorrhage or infiltrating leukocytes, immunocytochemistry using antibodies against Bcl-2 and Bax was performed on injured brain sections from patients after TBI (patients T2, T3, T5, and T6) and in controls (patients C1, C4, C5, and C6). Bcl-2 protein was detected in three of four TBI patients but in none of the controls. Bcl-2 protein was detected in cells with the morphological characteristics of neurons and endothelium, and other cells in which morphological type could not be distinguished after TBI ( Fig. 2A-C) . Bax protein was detected in all samples analyzed by immunocytochemistry. Bax protein was detected in cells with morphological characteristics of neurons, in other cells in which morphological type could not be distinguished after TBI, and in controls (Fig. 2, D-F ). These data demonstrate expression of Bcl-2 and Bax protein in parenchymal brain cells including neurons.
Cleavage of caspase-1 and up-regulation and cleavage of caspase-3 after TBI
To provide further evidence for the initiation of the PCD cascade after TBI, we examined expression of the caspases. Pro-caspase-1 is a 45-kDa protein that is activated when cleaved into 20-and 10-kDa subunits. In these experiments we used an antibody generated , and DNA fragmentation (J-L) after TBI. Due to autofluorescence in the tissues, images were collected using both red and green cubes, to discriminate between immunolabeling (red) and nonspecific autofluorescence (green or yellow). Bis-benzimide was also applied to the sections to identify cell nuclei (blue). A) Bcl-2 protein was not detected in sections from controls. B) Bcl-2 protein was detected in cells with the morphological features of neurons (arrows) in sections from patients after TBI but not in sections incubated without primary antibody (C). Bax protein was detected in cells with the morphological features of neurons (arrows) in sections from controls (D) and in patients after TBI (E), but not in sections incubated without primary antibody (F). Caspase-3 immunoreactivity was increased in cells with morphological appearance of neurons (arrows) and glia (arrowhead) in patients after TBI (H) compared with controls (G) and was not detected in sections incubated without primary antibody (I). Note the condensed nuclear material in the cells with increased caspase-3 immunoreactivity. Scattered populations of TUNEL-positive cells were detected in patients after TBI that had morphological characteristics of apoptosis (arrow) with condensed, fragmented nuclei (J) and necrosis (arrowhead) with swollen, diffusely labeled nuclei (K). TUNEL-positive cells were minimally detected in sections from most, but not all, control patients (L). Scale bar for A-F and J-L ϭ 30 m; scale bar for G-I ϭ 20 m. against the p10 fragment (amino acids 385-404) of human caspase-1 to detect both the intact 45-kDa and the cleaved 10-kDa proteins. Caspase-3 is a 32-kDa protein that is activated when cleaved into 17-and 12-kDa subunits. To detect caspase-3 we used a monoclonal antibody generated against the majority of the intact protein (amino acids 1-219) to detect the 32-kDa protein, or a polyclonal antibody generated against the intact protein to detect the 32-kDa and the cleaved 17-and 12-kDa proteins. Western blots showed that pro-caspase-1 was reduced in patients after TBI compared with controls (Fig. 3,  twofold reduction, Pϭ0.02) . In contrast, the p10 fragment of caspase-1 was increased in patients after TBI compared with controls (Fig. 3, 78 -fold increase, PϽ0.001). In addition to the p45 and p10 fragments, a distinct protein band of ϳ28 -30 kDa was also detected in samples from both TBI and control patients (Fig. 3A) . Preabsorption studies with the peptide used to generate the anti-caspase-1 p10 antibody showed that immunoblotting for all three bands was specific (Fig. 3B) . Thus, the 28-to 30-kDa protein could represent intermediate processing of caspase-1 or ICE␦, which is an alternatively spliced isoform of caspase-1 that contains the p10 sequence and inhibits apoptosis under some experimental conditions (27) . These data show that pro-caspase-1 is constitutively present and cleaved after TBI in humans. Intact caspase-3 was increased in patients after TBI compared with controls (Fig. 3, 14 -fold increase, Pϭ0.02). In addition, the cleaved 12-kDa fragment of caspase-3 was increased in patients after TBI compared with controls (Fig. 3, 19 -fold increase, Pϭ0.008). The 17-kDa fragment was also detected in four patients after TBI, but not in controls. These data show that caspase-3 is up-regulated and cleaved after TBI in humans.
Immunocytochemical studies also showed that caspase-3 was increased after TBI in humans compared with controls (Fig. 2, G--I) . Cells with the morphological appearance of neurons and glia showed increased immunoreactivity in contused brain after TBI. Several Figure 3 . Caspase-1 and -3 protein expression in patients after TBI. A) Pro-caspase-1 was reduced in pateints after TBI compared with controls. The p10 fragment of caspase-1 was increased in patients after TBI compared with controls. B) Preabsorption studies using the anti-caspase-1 p10 antibody incubated with or without the peptide used to generate the antibody. C) Both caspase-3 and the p12 fragment of caspase-3 were increased in patients after TBI compared with controls (there was insufficient sample to perform Western analysis using the polyclonal antibody against caspase-3 in patient T6). *PϽ0.05 vs. control, Mann-Whitney Rank Sum test; ROD, relative optical density. cells with increased caspase-3 immunoreactivity displayed condensed and shrunken nuclei as assessed by Hoechst staining (Fig. 2G) .
DNA fragmentation after TBI
TUNEL was performed in additional brain tissue sections to assess for evidence of DNA fragmentation after TBI (patients T1, T2, T3, T5, T6, and T7). Brain sections used for immunocytochemistry and TUNEL included contused but intact tissue. There were microscopic regions of tissue disruption and scattered microscopic hemorrhages, but in general the tissue examined consisted of intact parenchyma with selective cellular changes. Scattered populations of TUNELpositive cells were seen in most of the TBI patients examined. Both larger TUNEL-positive cells with the morphological characteristics of neurons and smaller TUNEL-positive cells, which could represent glia, infiltrated leukocytes, or oligodendrocytes, were seen (Fig.  2) . Some TUNEL-positive cells had the morphological features of apoptosis (shrunken, condensed, fragmented nucleus), whereas others had the morphological features of necrosis (swollen nucleus; Fig. 2 ). Areas of hemorrhage were seen in several of the sections; however, TUNEL-positive cells were primarily within the brain parenchyma. TUNEL-positive cells were also seen in cortical samples from two out of six control patients (patients C4 and C5); these patients had conditions for which this finding was not unexpected (Table 2) . TUNEL-positive cells in control patients primarily had morphological features of necrosis (data not shown).
DISCUSSION
In humans with severe TBI and life-threatening cerebral contusion: 1) Bcl-2, but not Bcl-x L or Bax, protein expression is increased, 2) caspase-1 is cleaved and caspase-3 is up-regulated and cleaved into fragments that would permit formation of their active enzyme complexes, 3) expression of Bcl-2, Bax, and caspase-3 was seen in cells in brain parenchyma (often with the morphological characteristics of neurons), and was not simply due to hemorrhage, and 4) evidence of late-stage PCD in the form of DNA fragmentation was also seen in injured brain. These results suggest that the PCD cascade is activated after TBI. These findings are the first to our knowledge that demonstrate participation of several key steps of the PCD cascade in brain in any acute human disease.
The caspase family consists of 13 currently identified cysteine proteases that also participate in the regulation and execution of cell death (28 -30) . Activated caspase-3 (Yama/Apopain/Cpp32) cleaves proteins important in the regulation of apoptosis, DNA repair, and cytoskeletal integrity, such as the inhibitor of caspase-activated deoxyribonuclease, DNA-dependent protein kinase, nuclear lamin, spectrin, and actin (31) (32) (33) . caspase-1 (ICE) cleaves prointerleukin-1 to active interleukin-1␤, a process that is important in the inflammatory response (30) and possibly reparative processes (34) . Caspases modulate cell death and brain injury in animal models of stroke (35) (36) (37) (38) and TBI. Yakovlev et al. (9) showed that caspase-1 and caspase-3 are activated and increased after experimental TBI in rats. The current finding that expression of caspase-3 is increased and that caspase-1 and caspase-3 are cleaved after TBI provide strong evidence that PCD is activated after TBI in humans and may contribute to secondary cell injury and cell death. Caspase activation may also produce beneficial effects after TBI, such as attenuating cellular energy depletion via cleavage of poly-(ADP)-ribose polymerase, an important mechanism in models of cerebral ischemia (39, 40) .
In vivo experimental models have shown that Bcl-2 family protein levels are altered after ischemic and traumatic insults (11, (23) (24) (25) . After TBI in rats, total Bcl-2 protein is increased in injured brain. Many neurons lacking Bcl-2 exhibit apoptotic morphologies, whereas those expressing Bcl-2 do not demonstrate biochemical or morphological features of apoptosis (11) . Thus, Bcl-2 protein expression is induced in neurons that are injured yet appear to survive. When Bcl-2 protein is overexpressed in vivo, neurons are resistant to ischemic injury (41) (42) (43) . These studies support the hypothesis that Bcl-2 protects neurons from injury. The present study in humans also demonstrates increased neuronal expression of Bcl-2. Thus, Bcl-2 expression could be an important factor that promotes survival of neurons injured after trauma.
Although Bcl-2 expression was increased, expression of Bax and Bcl-x L were not significantly increased after TBI. These results do not exclude the possibility that Bax and Bcl-x L also regulate neuronal death after TBI because translocation of Bax and Bcl-x L from cytosolic to mitochondrial locations, rather than alterations in protein expression levels itself is the key mechanism by which these Bcl-2 family genes control PCD (44) . Furthermore, the interaction of Bcl-2 protein deathantagonists to death-agonists has been proposed to determine whether a cell survives or dies after injury (1, 2, 45, 46) . It is important to point out; however, that Bax may act independently to promote cell death (47) , and whether intracellular heterodimeriztion occurs between Bax and Bcl-2 or Bcl-x L , is controversial (48, 49) .
This study, showing caspase activation and cleavage of DNA, demonstrates that trauma can initiate the PCD cascade in human brain. In the setting of trauma, PCD could be a maladaptive response that exacerbates injury. In animal models of ischemia and trauma, PCD that occurs within hours to days after injury appears to be deleterious to outcome. On the other hand, PCD could also be a physiological response to injury, participating in the remodeling of neuronal circuits or the culling of injured or dysfunctional cells after injury. There is progressive loss of cortical volume after TBI for weeks to months after injury (50), despite clinical improvement in patients during this interval, supporting the latter possibility.
Whether PCD that occurs after brain injury is maladaptive or beneficial has been addressed in several studies in animal models of stroke and trauma. Overexpression of Bcl-2 reduces neurological tissue damage in rodents after cerebral ischemia (42, 43 reduced post-traumatic apoptosis and improved neurological recovery after TBI (9) . Caspase inhibitors have also been shown to be effective in animal models of cerebral ischemia and excitotoxicity (35, 37) . These studies and the current findings suggest that PCD may exacerbate acute neurological damage after TBI in humans, beyond the damage produced from direct mechanical injury.
The use of experimental paradigms utilizing human tissues can demonstrate mechanistic evidence that corroborates in vitro and animal studies; however, inherent limitations in the use of clinical materials exist. Control brain samples, where normal brain tissue was removed under similar conditions, are not available. Furthermore, tissue samples from patients were removed at different times after injury. The samples may not be representative of changes in gene expression in the brains as a whole. For example, the samples may vary in their proximity to contusions, and the small sample size forbids histological analysis of adjacent tissue or comprehensive multi-label studies that are more feasible in experimental models. There are also differences in handling of tissues from patient samples compared to the autopsy control samples. Trauma patient samples were frozen within minutes after removal, whereas autopsy brains were much more slowly preserved. However, it is the trauma specimens that show evidence of caspase cleavage and DNA fragmentation, thus one cannot attribute the changes found in trauma brain tissue to post-mortem factors alone. Furthermore, the expression patterns of the proteins examined in this study are consistent with those seen in experimental models of brain injury where ideal controls were available. Nonetheless, differences in time between injury and surgery, region, severity, type of injury, and other factors cannot be controlled in this clinical study, possibly affecting detection of death regulatory genes. The results of this study need to be interpreted with the above limitations in mind.
In conclusion, several key steps in the PCD cascade have been identified in human brain after TBI. These findings demonstrate that genes that orchestrate PCD during central nervous system development can be reactivated in mature brain after trauma, and provide a rationale for the further development of pharmacological and molecular therapies targeting PCD after TBI, stroke, and other types of acute brain injury.
